Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Roberta Del Campo

Dermatology Miami Beach, FL Medical Doctor

NPI 1730491135 CMS profile 555071

555 Washington Avenue, S. 210, Miami Beach, FL 33139

Open in the dashboard

General payments

$207,288

316 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Roberta Del Campo of Miami Beach, FL is reported in the CMS Open Payments database as having received $207,288 across 316 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $70,346 70
2024 General $64,218 70
2023 General $3,207 19
2022 General $18,640 34
2021 General $20,685 33
2020 General $5,125 13
2019 General $25,068 77

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Roberta Del Campo
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Roberta Del Campo were reported at $70,346. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Roberta Del Campo Dermatology median Middle half National median
2019 $25,068 $454 $129–$1,240 $163
2020 $5,125 $235 $81–$756 $114
2021 $20,685 $377 $108–$1,108 $132
2022 $18,640 $514 $143–$1,391 $149
2023 $3,207 $607 $159–$1,674 $160
2024 $64,218 $751 $204–$1,903 $164
2025 $70,346 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Merz North America, Inc. $196,131 285 payments
  2. Revance Therapeutics, Inc. $10,547 3 payments
  3. Galderma Laboratories, L.P. $227 12 payments
  4. AbbVie, Inc. $136 5 payments
  5. Lilly USA, LLC $90 3 payments
  6. Allergan Inc. $72 4 payments
  7. Novartis Pharmaceuticals Corporation $45 2 payments
  8. Aclaris Therapeutics, Inc. $24 1 payment
  9. Regeneron Healthcare Solutions, Inc. $15 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $148,991 58 payments
  2. Travel and Lodging $27,918 41 payments
  3. Food and Beverage $22,380 216 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $8,000 1 payment
Products named General payments · program years 2019–2025
  1. Xeomin Dermatology $57,586 119 payments
  2. DAXXIFY $10,547 3 payments
  3. Xeomin musculoskeletal $2,503 12 payments
  4. ASCLERA $897 16 payments
  5. TALTZ $90 3 payments
  6. SKYRIZI Immunology $58 2 payments
  7. HUMIRA $45 2 payments
  8. COSENTYX $45 2 payments
  9. SKYRIZI Immunology $33 1 payment
  10. BOTOX COSMETIC $33 2 payments
  11. Other $67 3 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

17

Median for Dermatology: 534

Drug cost

$161

Median for Dermatology: $67,151

Branded share of claims

0%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Triamcinolone Acetonide Generic 17 $161

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DAXXIFY
  • REVANCE THERAPEUTICS, INC. $10,522
$10,522 — —
Xeomin
  • MERZ NORTH AMERICA, INC. $3,958
$3,958 — —
SKYRIZI
  • AbbVie, Inc. $33
$33 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

316 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record